Human CD14+CTLA‐4+ regulatory dendritic cells suppress T‐cell response by cytotoxic T‐lymphocyte antigen‐4‐dependent IL‐10 and indoleamine‐2,3‐dioxygenase production in hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Hepatology

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.26694PMID 23960017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

  2013influential reference
• Human CD1c (BDCA‐1)+ myeloid dendritic cells secrete IL‐10 and display an immuno‐regulatory phenotype and function in response to Escherichia coli

  2012cited by this paper
• Naturally occurring CD1c+ human regulatory dendritic cells: Immunoregulators that are expanded in response to E. coli infection

  2012cited by this paper
• Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation

  2012cited by this paper
• Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells.

  2012cited by this paper
• Immune regulatory function of B cells.

  2012cited by this paper
• Regulatory T cells: mechanisms of differentiation and function.

  2012cited by this paper
• Potential of immunotherapy for hepatocellular carcinoma.

  2011cited by this paper
• Regulatory T Cells

  2011cited by this paper
• Dendritic cells and the maintenance of self-tolerance

  2011cited by this paper
• CD68‐expressing cells can prime T cells and initiate autoimmune arthritis in the absence of reactive oxygen species

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Harnessing human dendritic cell subsets for medicine

  2010cited by this paper
• Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells

  2010cited by this paper
• The regulation of IL-10 production by immune cells

  2010cited by this paper
• Macrophages, innate immunity and cancer: balance, tolerance, and diversity.

  2010cited by this paper
• TPL-2 negatively regulates interferon-β production in macrophages and myeloid dendritic cells

  2009cited by this paper
• Tumor-Educated CD11bhighIalow Regulatory Dendritic Cells Suppress T Cell Response through Arginase I1

  2009cited by this paper
• Blood monocytes: development, heterogeneity, and relationship with dendritic cells.

  2009cited by this paper
• Human Liver Dendritic Cells Promote T Cell Hyporesponsiveness1

  2009cited by this paper
• Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β11

  2009cited by this paper
• CD69+CD4+CD25− T Cells, a New Subset of Regulatory T Cells, Suppress T Cell Proliferation through Membrane-Bound TGF-β11

  2009cited by this paper
• Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients

  2009cited by this paper
• CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance

  2009cited by this paper
• Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

  2008cited by this paper
• How regulatory T cells work

  2008cited by this paper
• Hepatic microenvironment programs hematopoietic progenitor differentiation into regulatory dendritic cells, maintaining liver tolerance.

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape

  2008cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance.

  2007cited by this paper
• Regulatory T cells and cancer.

  2007cited by this paper
• Regulatory T cells, tumour immunity and immunotherapy

  2006cited by this paper
• ERK1−/− Mice Exhibit Th1 Cell Polarization and Increased Susceptibility to Experimental Autoimmune Encephalomyelitis1

  2006cited by this paper
• Mechanisms of suppression by suppressor T cells

  2005cited by this paper
• Mechanisms of suppression by suppressor T cells

  2005cited by this paper
• Human T regulatory cells can use the perforin pathway to cause autologous target cell death.

  2004cited by this paper
• Ido expression by dendritic cells: tolerance and tryptophan catabolism

  2004cited by this paper
• Ligation of B7-1/B7-2 by Human CD4+ T Cells Triggers Indoleamine 2,3-Dioxygenase Activity in Dendritic Cells1

  2004cited by this paper
• Modulation of tryptophan catabolism by regulatory T cells

  2003cited by this paper
• B cells regulate autoimmunity by provision of IL-10

  2002cited by this paper

• Prognostic Value of the Ratio of Interleukin-2 and Interleukin-10 in Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Therapy

  2026cites this paper
• Multimodal clinical parameters-based immune status associated with the prognosis in patients with hepatocellular carcinoma

  2026cites this paper
• Clinical significance of AFP and PIVKA-II for predicting prognosis in hepatocellular carcinoma patients treated with immune checkpoint inhibitors

  2025cites this paper
• Myeloid cells in chronic liver inflammation

  2025cites this paper
• Unraveling the obesity paradox in hepatocellular carcinoma: relative role of elevated body mass index on detrimental effects of postoperative complications.

  2025cites this paper
• Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy

  2025cites this paper
• Cancer-associated fibroblast-derived exosomes in cancer progression: a focus on hepatocellular carcinoma.

  2025cites this paper
• Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review

  2025cites this paper
• Identification of a novel immature dendritic cell subset with potential pro-leukemic effects in leukemia microenvironment

  2025cites this paper
• Causal relationship of immune cell characteristics in hepatocellular carcinoma: A multi-omics analysis based on Mendelian randomization

  2025cites this paper
• Immune checkpoint biology in hepatocellular carcinoma (Review)

  2025cites this paper
• Immunomodulatory role of vitamin D and emerging immunotherapies in hepatocellular carcinoma

  2025cites this paper
• Epigenetic mechanisms in HCC immune landscape: Therapeutic implications.

  2025cites this paper
• Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?

  2025cites this paper
• Interplay between cancer-associated fibroblasts and dendritic cells: implications for tumor immunity

  2025cites this paper
• Colorectal cancer liver metastases: immune environment and therapeutic perspectives

  2025cites this paper
• Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy

  2025cites this paper
• Evaluation of the effects of Theranekron and Sorafenib treatments on alpha-fetoprotein, heat shock protein 90 alpha and indoleamine 2,3 dioxygenase 1 enzyme levels in experimental hepatocellular carcinoma in rats

  2025cites this paper
• Identification of a novel ferroptosis-related gene signature in hepatocellular carcinoma: clinical significance, tumor microenvironment, drug sensitivity, and gene landscape analysis

  2025cites this paper
• Unlocking the potential of chimeric antigen receptor T cell engineering immunotherapy: Long road to achieve precise targeted therapy for hepatobiliary pancreatic cancers.

  2025cites this paper
• Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises.

  2025cites this paper
• Improving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models

  2025cites this paper
• MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma

  2025cites this paper
• Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances

  2025cites this paper
• Identification of CAF signature genes and construction of CAF-based risk signature in hepatocellular carcinoma by multi-omics analysis

  2025cites this paper
• Hepatocellular Carcinoma and the Multifaceted Relationship with Its Microenvironment: Attacking the Hepatocellular Carcinoma Defensive Fortress

  2024cites this paper
• Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation.

  2024cites this paper
• Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication

  2024cites this paper
• CD276 Promotes an Inhibitory Tumor Microenvironment in Hepatocellular Carcinoma and is Associated with Poor Prognosis

  2024cites this paper
• Dendritic Cell-Related Gene Signatures in Hepatocellular Carcinoma: An Analysis for Prognosis and Therapy Efficacy Evaluation

  2024cites this paper
• Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma

  2024cites this paper
• Integrated analysis reveals an aspartate metabolism-related gene signature for predicting the overall survival in patients with hepatocellular carcinoma

  2024cites this paper
• Immunotherapy for hepatocellular carcinoma

  2024cites this paper
• Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future

  2024cites this paper
• BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4+ T-cell exhaustion

  2024cites this paper
• THE ROLE AND FUNCTION OF REGULATORY T CELLS (TREGS) IN PREGNANCY AND PREECLAMPSIA: A NARRATIVE REVIEW

  2024cites this paper
• Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

  2024cites this paper
• Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.

  2023cites this paper
• Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

  2023cites this paper
• Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma

  2023cites this paper
• The Synergistic Effect of Interventional Locoregional Treatments and Immunotherapy for the Treatment of Hepatocellular Carcinoma

  2023cites this paper
• High Indoleamine 2,3-Dioxygenase Expression along with Low Bridging Integrator-1 Expression in Hepatocellular Carcinoma Patients

  2023cites this paper
• The origins, roles and therapies of cancer associated fibroblast in liver cancer

  2023cites this paper
• Curcumin mediated dendritic cell maturation by modulating cancer associated fibroblasts-derived exosomal miRNA-146a

  2023cites this paper
• Deciphering the tumour immune microenvironment of hepatocellular carcinoma

  2023cites this paper
• Efferocytosis of viable versus heat-inactivated MSC induces human monocytes to distinct immunosuppressive phenotypes

  2023cites this paper
• Unfavorable tumor responses to immunotherapy in the liver: Lessons learned from clinical and preclinical studies

  2023cites this paper
• Novel Molecular Targets for Immune Surveillance of Hepatocellular Carcinoma

  2023cites this paper
• Mechanical confinement promotes heat resistance of hepatocellular carcinoma via SP1/IL4I1/AHR axis

  2023cites this paper
• New techniques: a roadmap for the development of HCC immunotherapy

  2023cites this paper
• Blockade of PD‐1 and CTLA‐4: A potent immunotherapeutic approach for hepatocellular carcinoma

  2023cites this paper
• Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials

  2023cites this paper
• New Therapeutics for HCC: Does Tumor Immune Microenvironment Matter?

  2022influential citation
• CTLA-4 silencing in dendritic cells loaded with colorectal cancer cell lysate improves autologous T cell responses in vitro

  2022cites this paper
• Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy

  2022cites this paper
• Prognostic potential and mechanism of SORT1 and its co‐expressed genes in hepatocellular carcinoma based on integrative analysis of multiple database

  2022cites this paper
• Immunohistochemical expression of CB1 receptors in the liver of patients with HBV related-HCC.

  2022cites this paper
• Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria

  2022cites this paper
• Resident Immune Cells of the Liver in the Tumor Microenvironment

  2022cites this paper
• PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

  2022cites this paper
• Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.

  2022cites this paper
• Advances of cancer-associated fibroblasts in liver cancer

  2022cites this paper
• A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma

  2022cites this paper
• Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?

  2022cites this paper
• Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer

  2022cites this paper
• Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy.

  2022cites this paper
• Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development

  2022cites this paper
• Personalized treatment for hepatocellular carcinoma: Current status and future perspectives

  2022cites this paper
• Immunotherapy in hepatocellular carcinoma.

  2022cites this paper
• Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?

  2022cites this paper
• The Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment

  2022cites this paper
• Emerging immunotherapy for HCC: A guide for hepatologists

  2022cites this paper
• Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma

  2022cites this paper
• Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

  2022cites this paper
• Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data.

  2022cites this paper
• Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma

  2022cites this paper
• Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside.

  2022cites this paper
• Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.

  2022cites this paper
• Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?

  2022cites this paper
• The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials

  2021cites this paper
• Emerging Roles on Immunological Effect of Indoleamine 2,3-Dioxygenase in Liver Injuries

  2021cites this paper
• Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy

  2021influential citation
• Immune Responses Following Locoregional Treatment for Hepatocellular Carcinoma: Possible Roles of Adjuvant Immunotherapy

  2021cites this paper
• Downregulated Ferroptosis-Related Gene STEAP3 as a Novel Diagnostic and Prognostic Target for Hepatocellular Carcinoma and Its Roles in Immune Regulation

  2021cites this paper
• Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma

  2021cites this paper
• Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers

  2021cites this paper
• ceRNA network development and tumor-infiltrating immune cell analysis in hepatocellular carcinoma

  2021cites this paper
• Immune-checkpoint inhibitors for advanced hepatocellular carcinoma: a synopsis of response rates.

  2021cites this paper
• Advances in immunotherapy for hepatocellular carcinoma

  2021cites this paper
• MSC-like cells increase ability of monocyte-derived dendritic cells to polarize IL-17-/IL-10-producing T cells via CTLA-4

  2021cites this paper
• Immunotherapies for hepatocellular carcinoma

  2021cites this paper
• A narrative review of systemic treatment options for hepatocellular carcinoma: state of the art review.

  2021cites this paper
• The footprint of kynurenine pathway in every cancer: A new target for chemotherapy.

  2021cites this paper
• Regulation of the Migration of Distinct Dendritic Cell Subsets

  2021cites this paper
• Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review

  2021cites this paper
• Innate immune cells and their interaction with T cells in hepatocellular carcinoma

  2020cites this paper
• Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer

  2020cites this paper
• Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

  2020influential citation
• Cytotoxic immune cell-based immunotherapy for hepatocellular carcinoma

  2020cites this paper
• Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus

  2020cites this paper